Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EBT (2016 - 2025)

Fennec Pharmaceuticals' EBT history spans 15 years, with the latest figure at $2.1 million for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 242.11% year-over-year to $2.1 million, compared with a TTM value of -$2.8 million through Dec 2025, down 1651.93%, and an annual FY2025 reading of -$9.6 million, down 179.92% over the prior year.
  • EBT for Q4 2025 was $2.1 million at Fennec Pharmaceuticals, up from -$623000.0 in the prior quarter.
  • The five-year high for EBT was $12.9 million in Q1 2024, with the low at -$8.0 million in Q3 2022.
  • Average EBT over 5 years is -$2.9 million, with a median of -$3.9 million recorded in 2021.
  • Biggest YoY gain for EBT was 316.58% in 2024; the steepest drop was 222.47% in 2024.
  • Tracing FENC's EBT over 5 years: stood at -$4.2 million in 2021, then crashed by 63.58% to -$6.9 million in 2022, then soared by 62.03% to -$2.6 million in 2023, then skyrocketed by 42.67% to -$1.5 million in 2024, then surged by 242.11% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's EBT are $2.1 million (Q4 2025), -$623000.0 (Q3 2025), and -$3.2 million (Q2 2025).